---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-011219"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:31:41.744913+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Intensity Therapeutics FY 2023 net loss $10.5M; cash $14.8M funds ops through Q1 2025

## Summary
- Net loss $10.5M in 2023 vs $7.6M in 2022; includes $2.3M non-cash loss on debt conversion.
- Year-end cash & investments $14.8M; company expects runway to end of Q1 2025.
- R&D expenses $4.8M (vs $5.1M); G&A $3.5M (vs $2.4M) due to public-company costs.
- Phase 3 sarcoma trial (INVINCIBLE-3) targeting 333 patients, overall survival endpoint; enrollment starts mid-2024.
- Phase 2/3 breast cancer program (INVINCIBLE-4) to begin mid-2024; endpoint pathological complete response rate.

## SEC filing metadata
- accession: 0001628280-24-011219
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000162828024011219/0001628280-24-011219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000162828024011219/intensity-20240314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-011219
- JSON: https://secwatch.observer/filing/0001628280-24-011219.json
- Plain text: https://secwatch.observer/filing/0001628280-24-011219.txt

## Key facts
- Earnings Releases
  INTENSITY THERAPEUTICS, INC. reported financial results for year ended December 31, 2023.
  - Period: year ended December 31, 2023
  - Result: reported results
  source text: On March 14, 2024, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567264/000162828024011219/0001628280-24-011219-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.